20.34
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences partners with SciBase for diagnostic tests - MSN
Castle Biosciences Inc (CSTL) Stock Price Down 4.54% on Jun 17 - GuruFocus
Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions - marketscreener.com
Castle Biosciences partners with SciBase for diagnostic tests (CSTL) - Seeking Alpha
Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases - MarketScreener
SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million - Yahoo Finance
Castle Biosciences Enters Collaboration and License Agreement wi - GuruFocus
Castle Biosciences (CSTL) Partners with SciBase for Dermatology Advancements | CSTL Stock News - GuruFocus
Castle Biosciences partners with SciBase to develop atopic dermatitis test - Investing.com
SciBase signs license agreement with Castle Biosciences to develop dermatology diagnostic tests - marketscreener.com
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - The Manila Times
Castle Biosciences Enters Collaboration and License - GlobeNewswire
New Diagnostic Test Could Predict Atopic Dermatitis Flares Before Symptoms Appear - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - Barchart.com
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention | CSTL Stock News - GuruFocus
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - The Manila Times
Castle Biosciences’ Chief Executive Officer Derek Maetzold - GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion ... - Bluefield Daily Telegraph
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - Barchart.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Two Sigma Advisers LP Acquires New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Squarepoint Ops LLC Lowers Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - The Manila Times
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
ProShare Advisors LLC Makes New $230,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 - Insider Monkey
Castle Biosciences Presents Innovative Research on Melanoma Risk Stratification at ASCO 2025 - Nasdaq
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
Man Group plc Buys Shares of 13,302 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Nuveen Asset Management LLC Has $12.41 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Deutsche Bank AG Buys 7,495 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Bank of America Corp DE Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences amends charter, stockholders vote By Investing.com - Investing.com India
Castle Biosciences Holds Annual Stockholders Meeting - TipRanks
Castle Biosciences amends charter, stockholders vote - Investing.com
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28% - simplywall.st
Castle Biosciences stock hits 52-week low at $15.66 By Investing.com - Investing.com Australia
Scotiabank Issues Pessimistic Forecast for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | C - GuruFocus
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Price Target Revised by Scotiabank | C - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healt - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | CSTL Stock News - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Castle Biosciences Executive Team Reveals Strategic Updates at Jefferies Healthcare Conference - Stock Titan
90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Has $8.42 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Northern Trust Corp Boosts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Jane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Voya Investment Management LLC Sells 668 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Price T Rowe Associates Inc. MD Purchases 1,837 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences confirms UM test’s efficacy - Investing.com
Castle Biosciences confirms UM test’s efficacy By Investing.com - Investing.com India
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Ri - GuruFocus
자본화:
|
볼륨(24시간):